The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 18, 2010
Filed:
May. 25, 1995
Steinunn Baekkeskov, San Francisco, CA (US);
Henk-jan Aanstoot, San Francisco, CA (US);
Pietro Decamilli, Guilford, CT (US);
Franco Folli, New Haven, CT (US);
Michele Solimena, New Haven, CT (US);
Steinunn Baekkeskov, San Francisco, CA (US);
Henk-Jan Aanstoot, San Francisco, CA (US);
Pietro Decamilli, Guilford, CT (US);
Franco Folli, New Haven, CT (US);
Michele Solimena, New Haven, CT (US);
The Regents of the University of California, Oakland, CA (US);
Yale University, New Haven, CT (US);
Abstract
Assays for the detection of diabetes and prediabetic status rely on exposing patient serum samples to purified ligand capable of binding autoantibodies specific for a 64kD autoantigen present on pancreatic β-cells. The purified ligand is usually purified glutamic acid decarboxylase (GAD) or a fragment or analog thereof. Preferably, the assays will detect the presence of antibodies to both lower molecular weight GAD and higher molecular weight GAD since diabetic and prediabetic status may be associated with only one of these two forms. The assays can be performed using conventional protocols, such as radioimmunoassay, enzyme-linked immunosorbent assay, and enzyme assay. Methods for treating diabetes comprise administering pharmaceutical compositions including the purified ligand, particularly when coupled to an immunoglobulin or lymphoid cell to induce tolerance. Alternatively, tolerance may be induced by administering attenuated T-helper cells, or isolated T-cell receptors, where the T-helper cells have been isolated based on their reactivity with GAD or equivalent ligand.